| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/28/2010 | EP2178559A2 Recombinant vibrio cholerae exotoxins |
| 04/28/2010 | EP2178558A2 Yersinia pestis antigens, vaccine compositions, and related methods |
| 04/28/2010 | EP2178557A1 Composition of tumour-associated peptides and related anti-cancer vaccine |
| 04/28/2010 | EP2178548A1 Survivin peptides as cancer vaccines |
| 04/28/2010 | EP2178540A1 Pharmaceutical composition suitable for adsorption to the cell surface of pathogenic microbes |
| 04/28/2010 | EP1599228B1 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 04/28/2010 | EP1556513B1 Compositions and methods for treating human papillomavirus-mediated disease |
| 04/28/2010 | EP1487854B1 Novel isoform of vascular endothelial cell growth inhibitor (vegi) |
| 04/28/2010 | EP1481062B1 Expec-specific proteins, genes encoding them and uses thereof |
| 04/28/2010 | EP1356067B1 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs |
| 04/28/2010 | EP1346036B1 Helper virus-free herpes virus amplicon particles and uses thereof |
| 04/28/2010 | EP1259606B1 Compositions useful for regulating parkin gene activity |
| 04/28/2010 | EP1246647B1 Non-immunosuppressant hiv tat |
| 04/28/2010 | CN1822856B HCV vaccines |
| 04/28/2010 | CN1820020B SARS-coronavirus virus-like particles and methods of use |
| 04/28/2010 | CN1798762B Tuberculosis vaccine with improved efficacy |
| 04/28/2010 | CN1796403B Polypeptide and bacterin for preventing and curing infection of polytype human being papilomavirus |
| 04/28/2010 | CN1777673B Treatment of IgA1 deposition diseases |
| 04/28/2010 | CN1703426B Humanized antibodies that recognize beta amyloid peptide |
| 04/28/2010 | CN1641034B Method for preparing tetanus toxin recombinant antigen and its use |
| 04/28/2010 | CN1555417B Paramyxovirus vector for gene transfer to the cardiovascular system |
| 04/28/2010 | CN1468307B Anti-dual integrin antibodies, compositions, methods and uses |
| 04/28/2010 | CN101698673A Prawn white spot syndrome virus VP37p polypeptide fragment and application thereof |
| 04/28/2010 | CN101698100A Listeriosis vaccine and preparation method |
| 04/27/2010 | USRE41277 protein D is an Ig receptor for human IgD and has an apparent molecular weight of 42,000; protein D can be detected in all of 116 encapsulated and non-encapsulated isolates of H. influenzae studied |
| 04/27/2010 | USRE41276 Strains of bacteria characterized by exhibiting a 7 alpha-dehydroxylase activity of less than 50%, and bile acid deconjugation activity of less than 50%, and descendants, mutants and derivatives thereof; for preventing and treating diseases associated with or caused by an altered metabolism of bile acids |
| 04/27/2010 | US7705195 Screening method |
| 04/27/2010 | US7705133 Transient receptor potential cation channel for use in identifying modulators for prevention and treatment of cell proliferative and nervous system disorders; hybridoma cell line; radioimmunoassay; kits |
| 04/27/2010 | US7705132 Stable polypeptide formulations |
| 04/27/2010 | US7705129 Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| 04/27/2010 | US7705016 administering small molecule capable of inhibiting CPT1(carnitine palmitoyl transferase1) is 2-tetradecylglydate (TDGA) or (R)-N-(tetradecylcarbamoyl)-aminocarnitine |
| 04/27/2010 | US7704979 Materials and methods for the treatment or prevention of obesity |
| 04/27/2010 | US7704973 Enhancing efficacy of antibodies bind to a cancer cell expressing CD20, HER2, epidermal growth factor receptor, or ganglioside 2 or 3 by orally administering a beta -glucan derived from barley having a backbone consisting of beta -(1,3) and beta -1,4) glycosidic linkages; low toxicity |
| 04/27/2010 | US7704970 DNA vaccination for treatment of autoimmune disease |
| 04/27/2010 | US7704969 Transfection complexes |
| 04/27/2010 | US7704964 Methods and compounds for the targeting of protein to exosomes |
| 04/27/2010 | US7704720 Propagating viral RNA sequences in host cells for use as tools in developing vaccines against viral infection; genetic vaccines; immunotherapy |
| 04/27/2010 | US7704524 Transdermal botulinum toxin administration for the treatment of spastic muscle pain |
| 04/27/2010 | US7704514 Vaccines |
| 04/27/2010 | US7704513 Nucleic acids and polypeptides specific for pathogenic strains of the Neisseria genus |
| 04/27/2010 | US7704512 Light chain that cleaves a neurosecretory protein; an HN domain that translocates the light chain across an endosome membrane and a substance P targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction |
| 04/27/2010 | US7704511 Combination of local botulinum toxin and oral triptan drug administration; preventing overuse; reducing pain sensory output |
| 04/27/2010 | US7704510 Viral surface protein fusion for use in generating immunoglobulin for treatment and prevention cytomagaloviral infection of endothelial and epithelial cells; immunotherapy |
| 04/27/2010 | US7704509 Producing an infectious, self-replicating, recombinant human parainfluenza viral particle for use in developing vaccine or preventative against respiratory tract infections |
| 04/27/2010 | US7704508 isolated and purified protein produced by a naturally occurring Babesia sp. and an isolated and purified nucleic acid encoding the above protein; use in diagnosing and treating a mammal infected with a Babesia sp. |
| 04/27/2010 | US7704507 Anticancer vaccine and diagnostic methods and reagents |
| 04/27/2010 | US7704506 Fcε-PE chimeric protein for targeted treatment of allergy responses a method for its production and pharmaceutical compositions containing the same |
| 04/27/2010 | US7704505 preventing a respiratory syncytial virus (RSV) infection which is MAb1129 by administering to a human in need thereof an effective amount of a humanized anti-RSV antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody |
| 04/27/2010 | US7704503 methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., in patients with cystic fibrosis |
| 04/27/2010 | US7704502 Combinations of antibodies selective for DR5 and other therapeutic agents |
| 04/27/2010 | US7704501 Antibodies binding to human ataxin-1-like polypeptide |
| 04/27/2010 | US7704499 Antibody against fragments of apo-lipoprotein B; for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases |
| 04/27/2010 | US7704498 Antiproliferative agents; anticancer agents; composition comprising antagonist of a human ErbB4 receptor, in admixture with a pharmaceutically acceptable carrier; antagonist selected from group consisting of an antibody produced by a hybridoma selected from the group containing HER4.10H1.1A1 |
| 04/27/2010 | US7704497 Molecules with extended half-lives, compositions and uses thereof |
| 04/27/2010 | US7704496 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocytes by contacting blood with polypeptide; cancer diagnosis |
| 04/27/2010 | US7704491 Recombinant human metapneumovirus and its use |
| 04/27/2010 | CA2438692C Injectable water-in-oil emulsions |
| 04/27/2010 | CA2413857C Pd-l2 molecules: pd-1 ligands and uses therefor |
| 04/27/2010 | CA2328431C Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis |
| 04/27/2010 | CA2303202C Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile toxins |
| 04/27/2010 | CA2293692C Methods and reagents for vaccination which generate a cd8 t cell immune response |
| 04/27/2010 | CA2278626C Novel method for the isolation of polysaccharides |
| 04/27/2010 | CA2222129C A method for producing influenza hemagglutinin multivalent vaccines |
| 04/27/2010 | CA2179909C Ligand that binds fas antigen |
| 04/22/2010 | WO2010045620A1 Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae |
| 04/22/2010 | WO2010045613A1 Immunoenhancer-linked oligomeric hiv vaccines |
| 04/22/2010 | WO2010045573A2 Tumor vaccine |
| 04/22/2010 | WO2010045506A2 Sustained drug delivery system |
| 04/22/2010 | WO2010045431A2 Dry powder formulations, vaccines and methods |
| 04/22/2010 | WO2010045388A2 Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis |
| 04/22/2010 | WO2010045344A1 Combination therapy comprising a c-met antagonist and a vegf antagonist |
| 04/22/2010 | WO2010045315A1 Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
| 04/22/2010 | WO2010045225A1 Induction of mucosal immune responses by mucosal delivery pentabody complex (mdpc) |
| 04/22/2010 | WO2010045193A1 Immunoglobulin variants and uses thereof |
| 04/22/2010 | WO2010045024A1 Biomarkers and methods for detecting and treating spinal and joint pain |
| 04/22/2010 | WO2010044921A2 Intranasal administration of receptor-binding ligands or genes encoding such ligands as a therapeutic regimen for mitigating infections caused by respiratory pathogens |
| 04/22/2010 | WO2010044919A2 Smallpox dna vaccine and the antigens therein that elicit an immune response |
| 04/22/2010 | WO2010044691A1 Immunosuppressive peptide |
| 04/22/2010 | WO2010044464A1 Modified amyloid beta peptide |
| 04/22/2010 | WO2010044451A1 Vaccine for treatment/prevention of scuticociliatosis in fish |
| 04/22/2010 | WO2010043977A2 Dengue virus neutralizing antibodies and uses thereof |
| 04/22/2010 | WO2010043842A1 Staphylococcus protein essential for growth |
| 04/22/2010 | WO2010043675A1 Pharmaceutical product for up-dosing of allergy vaccine |
| 04/22/2010 | WO2010043561A2 Regenerative therapy |
| 04/22/2010 | WO2010043259A1 Virus-like particles presenting hiv-1 envelopes, and methods for mucosal and sublingual immunization against hiv-1 using the same |
| 04/22/2010 | WO2010043232A1 Potato virus a coat protein-based vaccine for treating melanoma and its use |
| 04/22/2010 | WO2010043050A1 Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| 04/22/2010 | WO2010043039A1 Combination adjuvant formulation |
| 04/22/2010 | WO2010043037A1 Formulations targeting igfbp7 for diagnosis and therapy of cancer |
| 04/22/2010 | WO2010042970A1 A method of vaccination pigs |
| 04/22/2010 | WO2010017500A3 Anti-pancreatic cancer antibodies |
| 04/22/2010 | WO2010017209A3 Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine |
| 04/22/2010 | WO2010011879A3 Methods and compositions for treating and preventing autoimmune diseases |
| 04/22/2010 | WO2010009985A3 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| 04/22/2010 | WO2010004031A3 Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
| 04/22/2010 | WO2010003002A3 Modulation of follicular helper t cells |
| 04/22/2010 | WO2009158618A3 Avian reoviridae |
| 04/22/2010 | WO2009155723A3 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
| 04/22/2010 | WO2009155535A3 Compositions, methods and kits for eliciting an immune response |
| 04/22/2010 | WO2009127414A3 Inhibition of angiogenesis and tumor metastasis |